Summary of Study ST001090

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000729. The data can be accessed directly via it's Project DOI: 10.21228/M8FM38 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples | Perform analysis on untargeted data
Download mwTab file (text) | Download mwTab file(JSON) | Download data files

Study ID	ST001090
Study Title	NMR metabolomics study of Gemcitabine resistant cancer cells
Study Type	NMR metabolomics
Study Summary	1D 1H NMR spectra were collected from the samples and analyzed using MVAPACK software (http://bionmr.unl.edu/mvapack.php). Multivariate analysis was conducted to study the metabolic phenotypes of the samples.
Institute	University of Nebraska-Lincoln
Department	Chemistry
Laboratory	Dr. Robert Powers and Pankaj Singh labs
Last Name	Gebregiworgis
First Name	Teklab
Address	552 Hamilton Hall, 639 N. 12th Street, Lincoln, NE, 68588, USA
Email	teklab@huskers.unl.edu
Phone	(402) 472-3039
Submit Date	2018-09-25
Raw Data File Type(s)	fid
Analysis Type Detail	NMR
Release Date	2019-10-11
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR001148
Treatment Summary:	T3M4 wild type (WT) pancreatic cancer cells were cultured in DMEM with increasing concentrations of gemcitabine over a period of about 6 months. The resistance status of the cells at each gemcitabine dose was determined by calculating an IC50 using the MTT cytotoxicity assays. At the end of the 6-month treatment, the cell lines generated (GemR) were approximately 500-1000 fold resistant to gemcitabine as compared to the parental (WT) cells.Wild type T3M4 cells (WT), which are gemcitabine sensitive, and gemcitabine resistant T3M4 (GemR) were cultured with or without the addition of gemcitabine for the NMR metabolomics studies. A total of four cell culture groups were prepared that consisted of: (1) untreated T3M4 (WT) cells, (2) WT cells treated with 10 nM gemcitabine for a period of 12 hours (WT+), (3) untreated GemR cells, and (4) GemR cells treated with 10 nm gemcitabine for 12 hours (GemR+).

Treatment ID:

TR001148

Treatment Summary:

T3M4 wild type (WT) pancreatic cancer cells were cultured in DMEM with increasing concentrations of gemcitabine over a period of about 6 months. The resistance status of the cells at each gemcitabine dose was determined by calculating an IC50 using the MTT cytotoxicity assays. At the end of the 6-month treatment, the cell lines generated (GemR) were approximately 500-1000 fold resistant to gemcitabine as compared to the parental (WT) cells.Wild type T3M4 cells (WT), which are gemcitabine sensitive, and gemcitabine resistant T3M4 (GemR) were cultured with or without the addition of gemcitabine for the NMR metabolomics studies. A total of four cell culture groups were prepared that consisted of: (1) untreated T3M4 (WT) cells, (2) WT cells treated with 10 nM gemcitabine for a period of 12 hours (WT+), (3) untreated GemR cells, and (4) GemR cells treated with 10 nm gemcitabine for 12 hours (GemR+).